ARTICLE | Finance
$80M series B backs Oncologie's biomarkers, which could give new life to old therapies
Chinese VCs return to lead Oncologie's $80M series B, which will help the company reach the clinic and grow its pipeline
June 10, 2019 11:31 AM UTC
Oncologie's strategy of pairing in-licensed, later-stage compounds with biomarkers led Nan Fung Life Sciences and Pivotal bioVenture Partners China to return to invest in the cancer company's tranched $80 million series B.
The funds are expected to push Oncologie Inc. into the clinic. With a second tranche of roughly half the funds tied to an additional in-licensing deal, look for the company to round out its pipeline this year...